We are a biopharmaceutical company in the advanced stage of clinical research with a focus on identifying, creating, and marketing medications for the treatment of cancer. Our primary goal is to utilize our exclusive phospholipid drug conjugates™ (PDCs™) delivery system to produce PDCs that target cancer cells specifically, resulting in enhanced effectiveness and improved safety by minimizing off-target effects. The PDC™ platform holds the potential for finding and developing the next wave of cancer-targeting therapies, and we intend to independently develop PDCs and also engage in research and development partnerships.